Insider Transactions in Q3 2021 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$75,000
$15.06 P/Share
|
|
Sep 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.63 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
SELL
Open market or private sale
|
Direct |
6,000
-19.83%
|
$90,000
$15.35 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.15%
|
$45,000
$3.22 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
74,000
-100.0%
|
$1,110,000
$15.09 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71,000
+37.8%
|
$142,000
$2.61 P/Share
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
10,000
+50.0%
|
-
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.64%
|
-
|
|
Aug 31
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
314
+0.96%
|
$4,710
$15.92 P/Share
|
|
Aug 31
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+4.07%
|
$9,420
$15.92 P/Share
|
|
Aug 31
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,177
+1.5%
|
$17,655
$15.92 P/Share
|
|
Aug 31
2021
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+50.0%
|
$9,420
$15.92 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-62.5%
|
$75,000
$15.69 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+38.46%
|
$10,000
$2.63 P/Share
|